Quick Answer
Elicio Therapeutics, Inc. reported R&D Expense of $24.90 million for fiscal year 2025.
Elicio Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $24.90M | -26.0% |
| 2024 | $33.66M | +41.1% |
| 2023 | $23.85M | +31.7% |
| 2022 | $18.10M | -62.8% |
| 2021 | $48.70M | +24.9% |
| 2020 | $38.98M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $5.04M | -30.1% | -28.1% |
| June 30, 2025 | $7.01M | -14.4% | -9.9% |
| March 31, 2025 | $7.78M | +2.9% | +7.9% |
| September 30, 2024 | $7.21M | -0.8% | -11.9% |
| June 30, 2024 | $8.18M | +65.5% | +8.2% |
| March 31, 2024 | $7.56M | +37.8% | +4.1% |
| September 30, 2023 | $7.26M | +58.2% | +46.9% |
| June 30, 2023 | $4.94M | -1.9% | -9.8% |
- Elicio Therapeutics, Inc. showed a decrease of -26.0% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Elicio Therapeutics, Inc.’s r&d expense has declined by 36.1% (from $38.98 million to $24.90 million).
- The most recent figure is from Elicio Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: